GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Key facts

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Principal Investigator

Wei Liu

Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

Intervention

GVM±R regimen(drug)

Enrollment

115 enrolled

Eligibility

18-65 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, Tianjin Municipality, China

Collaborators

First Hospital of China Medical University · Hebei Medical University Fourth Hospital · Chengdu Shangjin Nanfu Hospital · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Xuanwu Hospital, Beijing · The Affiliated Ganzhou Hospital of Nanchang University · Beijing Tongren Hospital · The First Affiliated Hospital of Dalian Medical University · The First Hospital of Jilin University · People's Hospital of Zhengzhou University · The First Affiliated Hospital of Bengbu Medical University · The Second Affiliated Hospital of Kunming Medical University · The First Affiliated Hospital of Nanchang University · The Second Affiliated Hospital of Harbin Medical University · Shengjing Hospital · Peking University Third Hospital · First Affiliated Hospital of Harbin Medical University · China-Japan Friendship Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Aggressive B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNCT07474051
  Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
  AvenCell Therapeutics, Inc.
• RECRUITINGEARLY PHASE1NCT07344818
  An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
  Peking University People's Hospital
• RECRUITINGPHASE2NCT07097363
  Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
  University of Washington
• RECRUITINGPHASE2NCT06649812
  Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE2, PHASE3NCT07168980
  Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
  Children's Cancer Group, China
• RECRUITINGPHASE2NCT06996132
  Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT06834373
  Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
  Mayo Clinic
• RECRUITINGPHASE1, PHASE2NCT06536049
  Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Yazeed Sawalha

See all trials for Aggressive B-cell non-Hodgkin lymphoma →